Lead investigator, SURPASS-CVOT trial
Appears in 1 story
Published trial results in NEJM, December 2025
About 53,000 Americans with type 2 diabetes and heart disease were tracked through their insurance records. Those who started tirzepatide had a 2.9% risk of a heart attack, stroke, or cardiovascular death within a year, against 4.4% for a comparison drug.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
